FDA Declines to Approve ImmunityBio's Bladder Cancer Therapy, Shares Slump
Recommended
FDA Declines to Approve ImmunityBio's Bladder Cancer Therapy, Shares Slump
ImmunityBio Inc announced that the US FDA has declined to approve N-803 in combination with the Bacillus Calmette-Guérin vaccine for patients with BCG-unresponsive, non-muscle invasive bladder cancer due to application and manufacturing issues.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->